Survival analysis of 36 patients with malignant mesothelioma
SHEN Wei1, LIU Jiaqi2, CHEN Junfei2, YING Shibo2, XIA Hailing2, FENG Lingfang2, JIN Mingying2, JIANG Zhaoqiang2
1. Department of Respiratory Medicine, Cixi Third People's Hospital, Cixi, Zhejiang 315324, China; 2. School of Public Health, Hangzhou Medical College, Hangzhou, Zhejiang 310013, China
Abstract：Objective To analyze the survival of patients with malignant mesothelioma, so as to provide insights into the management of malignant mesothelioma. Methods Totally 36 patients with malignant mesothelioma admitted to Cixi Third People’s Hospital from October 2012 to January 2021 were enrolled, and the demographic features, exposure to asbestos, and diagnosis and treatment were retrospectively reviewed. The survival rate and median survival time were calculated with the life-table method, and the factors affecting the survival rate of malignant mesothelioma were identified using the Kaplan-Meier estimate and log-rank test. Results The 36 patients with malignant mesothelioma included 6 men ( 16.67% ) and 30 women ( 83.33% ), and had a median age of 61 ( interquartile range, 14 ) years. There were 30 cases with pleural malignant mesothelioma ( 83.33% ) and 6 cases with peritoneal malignant mesothelioma ( 16.67% ), 32 cases ( 88.89% ) with a history of occupational exposure to asbestos, and 26 cases ( 72.22% ) receiving palliative treatment. The 1-, 2- and 3-year cumulative survival rates were 30%, 15% and 3%, respectively, and the median survival time was 0.71 years. In addition, there were no significant differences in the survival period among patients with malignant mesothelioma in terms of gender, age, route of asbestos exposure, duration of asbestos exposure, pathogenic site and treatment regimens ( P>0.05 ). Conclusion The 36 patients with malignant mesothelioma had a median survival period of 0.71 years, and no association was found between the survival period and asbestos exposure or pathogenic site.
[1] The Global Cancer Observatory.Mesothelioma[EB/OL].[2021-10-08].https://gco.iarc.fr/today/data/factsheets/cancers/18-Mesothelioma-fact-sheet.pdf. [2] 陈凯燕,郭振英,苏丹,等.恶性间皮瘤在中国的发病及诊治现状分析[J].中华胸心血管外科杂志,2017,33(7):443-446. CHEN K Y,GUO Z Y,SU D,et al.Epidemiology and clinical diagnosis and treatment of malignant mesothelioma in China[J].Chin J Thorac Cardiovasc Surg,2017,33(7):443-446. [3] JIANG Z,CHEN T,CHEN J,et al.Hand-spinning chrysotile exposure and risk of malignant mesothelioma:a case-control study in Southeastern China[J].Int J Cancer,2018,142(3):514-523. [4] WOOLHOUSE I,MASKELL N A.Introducing the new BTS guideline:the investigation and management of pleural malignant mesothelioma[J].Thorax,2018,73(3):210-212. [5] SINHA S,SWIFT A J,KAMIL M A,et al.The role of imaging in malignant pleural mesothelioma:an update after the 2018 BTS Guidelines[J].Clin Radiol,2020,75(6):423-432. [6] KINDLER H L,ISMAILA N,ARMATO 3RD S G,et al.Treatment of malignant pleural mesothelioma:American Society of Clinical Oncology Clinical Practice Guideline[J].J Clin Oncol,2018,36(13):1343-1373. [7] 马建婷,傅云雀,杨春林,等.女性恶性腹膜间皮瘤52例预后因素分析[J].中国现代医生,2020,58(23):75-79. MA J T,FU Y Q,YANG C L,et al.An analysis of the prognostic factors in 52 cases of female malignant peritoneal mesothelioma[J].China Mod Doc,2020,58(23):75-79. [8] 李宁宁,白春梅,王颖轶,等.恶性腹膜间皮瘤25例临床分析[J].中国医学科学院学报,2018,40(2):211-218. LI N N,BAI C M,WANG Y Y,et al.Clinical analysis of 25 cases of malignant peritoneal mesothelioma[J].Acta Acad Med Sine,2018,40(2):211-218. [9] 黄显聪,李娜,陈忠坚,等.恶性胸膜间皮瘤临床病理特征及预后分析[J].中华肿瘤防治杂志,2019,26(22):76-80. HUANG X C,LI N,CHEN Z J,et al.Clinical characteristics and prognostic factors of malignant pleural mesothelioma[J].Chin J Cancer Prev Treat,2019,26(22):76-80. [10] 董良,赵建刚,王伟英,等.基于SEER数据库对恶性胸膜间皮瘤预后相关因素分析[J].浙江临床医学,2020,22(1):97-99. DONG L,ZHAO J G,WANG W Y,et al.Prognostic factor analysis of malignant pleural mesothelioma based on SEER database[J].Zhejiang Clin Med,2020,22(1):97-99. [11] 李娜,陈忠坚,毛伟敏.恶性腹膜间皮瘤的诊疗现状及进展[J].肿瘤防治研究,2020,47(12):992-995. LI N,CHEN Z J,MAO W M.Current status and progress on diagnosis and treatment of malignant peritoneal mesothelioma[J].Cancer Res Prev Treat,2020,47(12):992-995. [12] 常浩,余宗艳,王启明,等.120例恶性胸膜间皮瘤的临床特征及诊断分析[J].肿瘤,2020,40(3):199-205,214. CHANG H,YU Z Y,WANG Q M,et al.Clinical characteristics and diagnostic analysis of 120 cases with malignant pleural mesothelioma[J].Tumor,2020,40(3):199-205,214. [13] 杜琼,唐以军,王梅芳,等.22例恶性胸膜间皮瘤的回顾性分析[J].湖北医药学院学报,2019,38(4):369-372. DU Q,TANG Y J,WANG M F,et al.A retrospective analysis of 22 cases of malignant pleural mesothelioma[J].J Hubei Univ Med,2019,38(4):369-372. [14] 曾艳,童瑞,王翔耀,等.恶性腹膜间皮瘤26例临床特点及预后影响因素分析[J].解放军医学院学报,2015,36(6):559-562,567. ZENG Y,TONG R,WANG X Y,et al.Clinical characteristics and prognostic factors of patients with malignant peritoneal mesothelioma:an analysis of 26 cases[J].Acad J Chin PLA Med Sch,2015,36(6):559-562,567.
